

# Sarah-Jane Dawson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6355800/sarah-jane-dawson-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48  
papers

7,741  
citations

27  
h-index

54  
g-index

54  
ext. papers

9,640  
ext. citations

21.1  
avg, IF

5.36  
L-index

#	Paper	IF	Citations
48	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. <i>Oncologist</i> , <b>2022</b> ,	5.7	4
47	Non-genetic determinants of malignant clonal fitness at single-cell resolution. <i>Nature</i> , <b>2021</b> ,	50.4	2
46	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , <b>2021</b> ,	50.4	15
45	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , <b>2021</b> , 12, 1434	17.4	5
44	Detection of cell-free microbial DNA using a contaminant-controlled analysis framework. <i>Genome Biology</i> , <b>2021</b> , 22, 187	18.3	5
43	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. <i>Nature Medicine</i> , <b>2021</b> , 27, 1006-1011	50.5	13
42	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	8
41	Liquid biopsies for residual disease and recurrence.. <i>Med</i> , <b>2021</b> , 2, 1292-1313	31.7	1
40	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. <i>Science</i> , <b>2020</b> , 368, 387-394	33.3	146
39	Combining liquid biopsies and PET-CT for early cancer detection. <i>Nature Medicine</i> , <b>2020</b> , 26, 1010-1011	50.5	4
38	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. <i>Blood</i> , <b>2020</b> , 136, 572-584	2.2	19
37	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003363	11.6	7
36	HBO1 is required for the maintenance of leukaemia stem cells. <i>Nature</i> , <b>2020</b> , 577, 266-270	50.4	47
35	Non-genetic mechanisms of therapeutic resistance in cancer. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 743-756	31.3	94
34	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , <b>2019</b> , 36, 385-401.e8	24.3	169
33	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. <i>Nature Communications</i> , <b>2019</b> , 10, 2723	17.4	67
32	Characterizing the Cancer Genome in Blood. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2019</b> , 9,	5.4	5

31	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , <b>2019</b> , 134, 756-756	2.2	15
30	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , <b>2019</b> , 9, 354-369	24.4	60
29	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 134, 39-45	7	129
28	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , <b>2019</b> , 25, 119-129	50.5	94
27	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , <b>2018</b> , 244, 616-627	9.4	62
26	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1211-1223	59.2	226
25	Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1055-1055	2.2	3
24	Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 883-892	5.1	57
23	Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1274-1280	2.2	122
22	Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. <i>Blood</i> , <b>2017</b> , 129, 1685-1690	2.2	42
21	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 869-870	8.9	6
20	Click chemistry enables preclinical evaluation of targeted epigenetic therapies. <i>Science</i> , <b>2017</b> , 356, 1397-1401	33.9	78
19	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. <i>Nature Communications</i> , <b>2017</b> , 8, 14756	17.4	44
18	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-14	3.6	25
17	The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. <i>Nature Communications</i> , <b>2016</b> , 7, 11479	17.4	779
16	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , <b>2016</b> , 23, 673-81	17.6	69
15	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002204	11.6	81
14	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 1010-1014	44.5	46

13	Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. <i>Cancer Research</i> , <b>2016</b> , 76, 5590-5591	50.1	4
12	Large B-cell lymphoma: is the future written in the blood?. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 481-3	21.7	3
11	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 8760	17.4	334
10	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , <b>2015</b> , 525, 538-42	50.4	345
9	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 406-14	21.7	566
8	A new genome-driven integrated classification of breast cancer and its implications. <i>EMBO Journal</i> , <b>2013</b> , 32, 617-28	13	212
7	Analysis of circulating tumor DNA to monitor metastatic breast cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1199-209	59.2	1560
6	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. <i>Nature</i> , <b>2013</b> , 497, 108-12	50.4	1220
5	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 136ra68	17.5	882
4	Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 225-32	2.2	16
3	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 547-52	2.4	42
2	Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 104-7		3
1	Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study		2